Eversense for 180 days: a user’s perspective

Big news at ADA 78th Scientific Sessions this year was the FDA approval of Senseonics’ Eversense device: the first implantable Continuous Glucose Monitor.    The featured picture here shows where the on-body transmitter is worn by a gentleman who has been using it for 180 days in Germany.     Fewer start-up days, less down-time and higher rate of accuracy are some of the advantages shown in the clinical trial, when compared to other CGM devices.  People who prefer not to have to insert something into their skin themselves will be pleased to know that the insertion of a tiny sensor  is performed entirely by the physician in a 10-minute outpatient office procedure.   Here’s a 2 minute video showing how it works:  https://www.eversensediabetes.com/eversense-cgm-system/

The sensor is about half the length of a match and about as big around.    Training and certification for the physician is scheduled and performed by Eversense staff at the physician’s office.     Users need to return to the physician’s office every 90 days to get the sensor exchanged for a new one in the opposite arm.   The user who spoke at the product theater presentation for Eversense mentioned that he has already worn the system during several marathons and triathlons with greater peace of mind and no technical issues.   He likes the unobtrusive, quiet, on-body vibration that alerts him to changing trends in his blood glucose patterns.   His family and friends also like it because it gives them greater peace of mind so much that they almost forget he has diabetes.

Eversense will be taking its “Ever Mobile” lab unit across the country to introduce the technology to  health care professionals.   “Research has repeatedly demonstrated the clinical benefits patients experience with regular CGM use, including improved glucose control and protection against severe hypoglycemia,” said Steven Edelman, MD, @TCOYD Professor of Medicine at University of California San Diego, Founder & Director of Taking Control of Your Diabetes, and Senseonics Board member.  “Despite these benefits, a significant number of people with diabetes do not use, or have access to, continuous glucose monitoring. Furthermore, the data shows that many people who’ve tried traditional CGM in the past either don’t wear it as often as they should or don’t stick with it for a variety of reasons, including concerns surrounding sensor accuracy, sensor insertion, and sensor discomfort. So, it’s important that patients have choices and that medical device companies continue to advance the field of CGM with innovations that make it easier for the end user.”   In this really great video,  Dr. Edelman outlines the benefit of this for people with type 1 and type 2 diabetes:

https://www.multivu.com/players/English/8333951-senseonics-continuous-glucose-monitoring-fda-approval/

It is wonderful to have more choices for patients,  which will lead to greater acceptance of CGM technology and better blood glucose control.  Less hypoglycemia, more time in range = more you.

 

 

2 thoughts on “Eversense for 180 days: a user’s perspective

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s